Cargando…
Recombinant nanocomposites by the clinical drugs of Abraxane(®) and Herceptin(®) as sequentially dual-targeting therapeutics for breast cancer
Breast cancer greatly threatens the health of women all over the word despite of several effective drugs. Targeted therapy for breast cancer is limited to human epidermal growth factor receptor 2 (HER2). Herceptin(®), monoclonal antibody against HER2, is now widely used in HER2(+) breast cancer. Abr...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Ivyspring International Publisher
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820917/ https://www.ncbi.nlm.nih.gov/pubmed/29483955 http://dx.doi.org/10.7150/jca.22163 |